# From Anxiety, Depression to Major Neurocognitive Disorders: Exploring Their Association With the Risk Factors for Dementia

**Authors:** Ali A Sulais, Nada Al Zamil

PMC · DOI: 10.7759/cureus.101994 · Cureus · 2026-01-21

## TL;DR

This paper reviews how mental health conditions like depression and anxiety may increase dementia risk and explores possible mechanisms and prevention strategies.

## Contribution

The paper systematically reviews how psychiatric disorders and related factors contribute to dementia risk and cognitive decline.

## Key findings

- Mental health disorders like depression and anxiety are linked to increased dementia risk.
- Chronic stress and sleep disturbances may contribute to neurocognitive decline.
- Psychopharmacological treatments could influence long-term cognitive outcomes.

## Abstract

Dementia presents an escalating public health challenge worldwide. While traditional risk factors such as metabolic syndromes and lifestyle choices have been widely examined, growing evidence highlights the role of mental health conditions in the development of dementia. Our manuscript is a narrative review of peer-reviewed systematic reviews and meta-analyses examining the association between common psychiatric disorders, namely depression, bipolar disorder, anxiety, post traumatic stress disorder (PTSD), schizophrenia, and the onset of neurocognitive decline. Additional factors such as chronic stress, sleep disturbances, and exposure to traumatic life events are also considered. Proposed mechanisms include endocrine dysregulation, neuroinflammation, and altered immune responses. The review further explores how psychopharmacological interventions may influence cognitive outcomes later in life. These insights aim to enhance clinicians’ ability to identify at-risk populations and inform preventive strategies.

## Linked entities

- **Diseases:** dementia (MONDO:0001627), depression (MONDO:0002050), bipolar disorder (MONDO:0004985), anxiety (MONDO:0005618), schizophrenia (MONDO:0005090)

## Full-text entities

- **Genes:** APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}
- **Diseases:** agitation (MESH:D011595), cardiovascular disease (MESH:D002318), infections (MESH:D007239), Neurocognitive Disorders (MESH:D019965), endocrine dysregulation (MESH:D004700), deficits in memory, attention, and other executive functions (MESH:D001289), psychosis (MESH:D011618), vascular damage (MESH:D057772), osteoporosis (MESH:D010024), vascular dementia (MESH:D015140), hypertension (MESH:D006973), death (MESH:D003643), atherosclerosis (MESH:D050197), frontotemporal dementia (MESH:D057180), prolonged wakefulness (MESH:D008133), panic attack (MESH:D016584), cognitive decline (MESH:D003072), deficits in memory, processing, and executive functioning (MESH:D008569), Depression (MESH:D003866), bipolar (MESH:D001714), Dementia (MESH:D003704), coronary artery disease (MESH:D003324), Mental Disorders (MESH:D001523), depressive cognitive impairment (MESH:D060825), Alzheimer's Disease (MESH:D000544), neurotoxic (MESH:D020258), Insomnia (MESH:D007319), diabetes (MESH:D003920), Lewy body dementia (MESH:D020961), Anxiety (MESH:D001007), atrophy (MESH:D001284), Dementia praecox (MESH:D012559), neuroinflammation (MESH:D000090862), neurodegeneration (MESH:D019636), inflammatory (MESH:D007249), metabolic syndromes (MESH:D024821), fractures (MESH:D050723), impaired immunity (MESH:D020274), Impaired sleep (MESH:D012893), dyslipidemia (MESH:D050171), MDD (MESH:D003865), metabolic diseases (MESH:D008659), substance misuse (MESH:D009293), PTSD (MESH:D013313), hyperactivity (MESH:D006948), Anxiety disorders (MESH:D001008), trauma-related disorders (MESH:D000068099), HPA hyperactivity (MESH:D007029), falls (MESH:C537863), obesity (MESH:D009765), fatigue (MESH:D005221), hypercoagulability (MESH:D019851)
- **Chemicals:** valproate (MESH:D014635), antiseizure medications (-), Benzodiazepines (MESH:D001569), olanzapine (MESH:D000077152), amisulpride (MESH:D000077582), ziprasidone (MESH:C092292), Quetiapine (MESH:D000069348), steroid (MESH:D013256), carbamazepine (MESH:D002220), clonazepam (MESH:D002998), corticosterone (MESH:D003345), adrenaline (MESH:D004837), haloperidol (MESH:D006220), risperidone (MESH:D018967), lithium (MESH:D008094), trazodone (MESH:D014196)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12922723/full.md

## References

70 references — full list in the complete paper: https://tomesphere.com/paper/PMC12922723/full.md

---
Source: https://tomesphere.com/paper/PMC12922723